T Cell Activation and Expansion Patents: Who Leads, Where Gaps Are 2026
T Cell Activation and Expansion Patents: Mapping Who Leads and Where the Filing Gaps Sit
37.9% concentration. The five leading assignees hold 2,030 of the 5,361 records in scope — a concentrated top with a long single-filer tail behind it. Filings climbed to 711 in 2019, the peak year so far, then eased to 495 by 2021 and 365 by 2024 — a 26% decline over that three-year window. 2017 opened at 326. Because publication lags filing by roughly 18 months, the 2025 and 2026 counts (36 in the most recent year) are still incomplete and should not be read as a continued fall.
- 1IOVANCE BIOTHERAPEUTICS INC11.6%
- 2NOVARTIS AG9.8%
- 3THE TRUSTEES OF THE UNIV OF PENNSYLVANIA8.6%
- 4JUNO THERAPEUTICS INC4.2%
- 5REGENERON PHARMACEUTICALS INC3.6%
See the full t cell activation and expansion analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Questions practitioners ask about this landscape
Who holds the most patents in T cell activation and expansion?
The assignee ranking in this dataset covers 100 companies, and the leader holds 622 of the 5,361 records in scope, well ahead of the fifth-place holder at 195 and the tenth-place holder at 82. That gap marks a clear leader rather than a tightly bunched top group. Beyond the leading names, the ranking thins out quickly into a long tail of assignees with only a handful of filings each, so a full freedom-to-operate check needs to look well past the largest names.
Is patent filing in this field growing or slowing down?
Filing peaked at 711 records in 2019 and has pulled back since, falling from 495 in 2021 to 365 in 2024, a 26% decline over that span. That is a real pullback, not a plateau. Because publication typically lags filing by about 18 months, the very latest years in any dataset always look artificially low, so treat 2025-2026 counts as incomplete rather than as evidence the field has stopped moving.
What is the difference between activation beads and cytokine cocktail approaches?
Activation beads use surface-bound antibodies, typically anti-CD3 and anti-CD28, to physically engage T cell receptors and drive proliferation, while cytokine cocktails rely on soluble signalling molecules like IL-2, IL-7 and IL-15 added directly to the culture medium. Many filings in this landscape combine both approaches, using beads for initial activation and cytokine cocktails to sustain expansion and shape memory phenotype. The representative recent filing in this dataset, a serum-free formula built around a five-cytokine combination, illustrates the cocktail side of that split.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on T Cell Activation and Expansion covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.